Stay updated with breaking news from Nasdaq Regn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Wednesday. Several other research analysts have also recently weighed in on REGN. Piper Sandler increased their price target on shares of Regeneron Pharmaceuticals from $885.00 to $895.00 and gave […]
Geneos Wealth Management Inc. lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 10.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 906 shares of the biopharmaceutical company’s stock after selling 102 shares during the period. Geneos Wealth Management Inc.’s holdings in Regeneron […]
Portside Wealth Group LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 398 shares of the biopharmaceutical company’s stock, valued at approximately $286,000. Other large investors also […]
Heartland Bank & Trust Co increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 9.6% in the third quarter, HoldingsChannel.com reports. The firm owned 992 shares of the biopharmaceutical company’s stock after acquiring an additional 87 shares during the quarter. Heartland Bank & Trust Co’s holdings in Regeneron Pharmaceuticals were […]
BROOKFIELD Corp ON increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 8.7% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 29,626 shares of the biopharmaceutical company’s stock after acquiring an additional 2,366 shares during the quarter. BROOKFIELD Corp ON’s holdings in Regeneron Pharmaceuticals were worth $21,287,000 at the end […]